Oncology

Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status

September 19th 2021, 7:47pm

Article

Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.

In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1

September 19th 2021, 2:00pm

Article

The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”

Spotlighting Social, Emotional Needs in Underserved Populations With Cancer

September 14th 2021, 1:00pm

Article

Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.

Dr Gary Lyman: Pandemic Barriers Led to More Late-Stage Cancer Presentations

September 8th 2021, 4:55pm

Video

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how doctors are managing patients who present with later-stage cancers as a result of barriers to screening measures imposed by the pandemic.

Study: PET/CT Scans Predict for Response in Salvage-Stage DLBCL

September 5th 2021, 11:00am

Article

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

A Review of Standard of Care in DLBCL

August 29th 2021, 11:36am

Article

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

Genomic Complexity Linked With Poor Outcomes in DLBCL

August 16th 2021, 9:20pm

Article

A new report could eventually help investigators better understand which patients with diffuse large B-cell lymphoma (DLBCL) are most likely to respond to certain therapies.

High-Dose Methotrexate Effective in Preventing Isolated CNS Relapse in Diffuse Large B-Cell Lymphoma

August 13th 2021, 6:30pm

Article

Risk of isolated central nervous system (CNS) involvement was found to be significantly lower in patients with diffuse large B-cell lymphoma who received high-dose methotrexate vs RCHOP chemotherapy, although risk of concomitant CNS-systemic relapse rates were similar between both groups.

Meta-Analysis Finds CIT Regimens Associated With Improved Survival, Safety Outcomes in NSCLC

August 11th 2021, 6:30pm

Article

Due to the lack of head-to-head trials comparing chemoimmunotherapy regimens with chemotherapy alone as first-line treatment for non-small cell lung cancer, researchers conducted a network meta-analysis of 17 randomized controlled trials of patients with the cancer.

An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations

August 1st 2021, 1:00pm

Article

On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.